Back to Search Start Over

Glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use among adults with diabetes mellitus by cardiovascular-kidney disease risk: National Health and Nutrition Examination Surveys, 2015–2020

Authors :
Jacobs, Joshua A.
Zheutlin, Alexander R.
Derington, Catherine G.
King, Jordan B.
Pandey, Ambarish
Bress, Adam P.
Source :
American Journal of Preventive Cardiology; March 2024, Vol. 17 Issue: 1
Publication Year :
2024

Abstract

•GLP1-RAs and SGLT2Is lower the risk of adverse cardiac-kidney events in diabetes.•Only 10 % used GLP1-RAs or SGLT2Is, regardless of level of cardiac-kidney risk.•Few people who would benefit most from GLP1-RAs or SGLT2Is, were receiving them from 2015 to 2020.

Details

Language :
English
ISSN :
26666677
Volume :
17
Issue :
1
Database :
Supplemental Index
Journal :
American Journal of Preventive Cardiology
Publication Type :
Periodical
Accession number :
ejs64698879
Full Text :
https://doi.org/10.1016/j.ajpc.2023.100624